Fas and mutant estrogen receptor chimeric gene: A novel suicide vector for tamoxifen-inducible apoptosis

Japanese Journal of Cancer Research

Volumn 89, Issue 7, 1998, Pages 741-747

  Kodaira, Hiroshi ^a,b   Kume, Akihiro ^a   Ogasawara, Yoji ^a   Urabe, Masashi ^a   Kitano, Kiyoshi ^b   Kakizuka, Akira ^c   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

Fas; Gene therapy; Inducible apoptosis; Mutant estrogen receptor; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; CHIMERIC PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; FAS ANTIGEN; HYBRID PROTEIN; MUTANT PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENETIC TRANSDUCTION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE;

EID: 0031687252     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03279.x     Document Type: Article

References (36)

1. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46, 5276-5281 (1986).
2. Obaru, K., Fujii, S., Matsushita, S., Shimada, T. and Takatsuki, K. Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. Hum. Gene Ther., 7, 2203-2208 (1996).
3. Franken, M., Estabrooks, A., Cavacini, L., Sherburne, B., Wang, F. and Scadden, D. T. Epstein-Burr virus-driven gene therapy for EBV-related lymphomas. Nut. Med., 2, 11379-1382 (1996).
4. Bordignon, C., Bonini, C., Verzeletti, S., Nobili, N., Maggioni, D., Traversari, C., Giavazzi, R., Servida, P., Zappone, E., Benazzi, E., Bernardi, M., Porta, F., Ferrari, G., Mavilio, F., Rossini, S., Blaese, R. M. and Candotti, F. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum. Gene Ther., 6, 813-819 (1995).
5. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. and Bordignon, C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276, 1719-1724 (1997).
6. Aoki, Y., Tani, K., Takahashi, K., Fukushima, M., Ozawa, K. and Asano, S. Regulation of recombinant human granulocyte colony-stimulation factor production using herpes simplex virus 1 thymidine kinase gene. Biochem. Biophys. Res. Commun., 200, 1245-1251 (1994).
7. Borrelli, F., Heyman, R., Hsi, M. and Evans, R. M. Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. USA, 85, 7572-7576 (1988).
8. Heyman, R. A., Borrelli, E., Lesley, J., Anderson, D., Richman, D. D., Baird, S. M., Hyman, R. and Evans, R. M. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc. Natl. Acad. Sci. USA, 86, 2698-2702 (1989).
9. Lupton, S. D., Brunton, L. L., Kalberg, V. A. and Overell, R. W. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol., 11, 3374-3378 (1991).
10. Anderson, W. F. Gene therapy for cancer. Hum. Gene Ther., 5, 1-2 (1994).
11. Takebayashi, H., Oida, H., Fujisawa, K., Yamaguchi, M., Hikida, T., Fukumoto, M., Narumiya, S. and Kakizuka, A. Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo. Cancer Res., 56, 4164-4170 (1996).
12. Kokubun, M., Kume, A., Urabe, M., Mano, H., Okubo, M., Kasukawa, R., Kakizuka, A. and Ozawa, K. Apoptosis-mediated regulation of recombinant human granulocyte colony-stimulating factor production by genetically engineered fibroblasts. Gene Ther., 5 (1998). in press.
13. Picard, D. Steroid-binding domains for regulating the functions of hctcrologous proteins in cis. Trends Cell Biol., 3, 278-280 (1993).
14. Mattioni, T., Louvion, J.-F. and Picard, D. Regulation of protein activities by fusion to steroid binding domains. Methods Cell Biol., 43, 335-352 (1994).
15. Berthois, Y., Katzenellenbogen, J. A. and Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA, 83, 2496-2500 (1986).
16. Osborne, C. K., Hobbs, K. and Clark, G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res., 45, 584-590 (1985).
17. Danielian, P. S., White, R., Hoare, S. A., Fawell, S. E. and Parker, M. G. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol. Endocrinol., 7, 232-240 (1993).
18. Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G. and Evan, G. I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res., 23, 1686-1690 (1995).
19. Morgan, R. A., Couture, L., Elroy-Stein, O., Ragheb, J., Moss, B. and Anderson, W. F. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res., 20, 1293-1299 (1992).
20. Urabe, M., Hasumi, Y., Ogasawara, Y., Matsushita, T., Kamoshita, N., Nomoto, A., Colosi, P., Kurtzman, G. J., Tobita, K. and Ozawa, K. A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome. Gene, 200, 157-162 (1997).
21. German, C., Padmanabhan, R. and Howard, B. H. High efficiency DNA-mediated transformation of primate cells. Science, 221, 551-553 (1983).
22. Onishi, M., Kinoshita, S., Morikawa, Y., Shibuya, A., Phillips, J., Lanier, L. L., Gorman, D. M., Nolan, G. P., Miyajima, A. and Kitamura, T. Applications of retrovirus-mediated expression cloning. Exp. Hematol., 24, 324-329 (1996).
23. Sanford, K. K., Hobbs, G. L. and Earle, W. R. The tumor-producing capacity of strain L mouse cells after 10 years in vitro. Cancer Res., 15, 162-166 (1956).
24. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y. and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 233-243 (1991).
25. Watanabe-Fukunaga, R., Brannan, C. I., Itoh, N., Yonehara, S., Copeland, N. G., Jenkins, N. A. and Nagata, S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol., 148, 1274-1279 (1992).
26. Itoh, N. and Nagata, S. A novel protein domain required for apoptosis. J. Biol. Chem., 268, 10932-10937 (1993).
27. Ushiroyama, T., Yoshikawa, M., Saeki, M., Okuda, K. and Sugimoto, O. Hypergonadotropinemia with estradiol secretion in peri- and postmenopausal period. Acta Obstet. Gynecol. Scand., 68, 139-143 (1989).
28. Ushiroyama, T. and Sugimoto, O. Endocrine function of the peri- and postmenopausal ovary. Horm. Res., 44, 64-68 (1995).
29. Chinnaiyan, A. M., O'Rourke, K., Tewari, M. and Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81, 505-512 (1995).
30. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H. and Wallach, D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem., 270, 7795-7798 (1995).
31. Hsu, H., Xiong, J. and Goeddel, D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell, 81, 495-504 (1995).
32. Stanger, B. Z., Leder, P., Lee, T.-H., Kim E. and Seed, B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell, 81, 513-523 (1995).
33. Ting, A. T., Pimentel-Muiños, F. X. and Seed, B. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J., 15, 6189-6196 (1996).
34. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J. and Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science, 276, 111-113 (1997).
35. Pan, G., Ni, J., Wei, Y.-F., Yu, G.-I., Gentz, R. and Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815-818 (1997).
36. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P. and Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-821 (1997).